JP2009530299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530299A5 JP2009530299A5 JP2009500498A JP2009500498A JP2009530299A5 JP 2009530299 A5 JP2009530299 A5 JP 2009530299A5 JP 2009500498 A JP2009500498 A JP 2009500498A JP 2009500498 A JP2009500498 A JP 2009500498A JP 2009530299 A5 JP2009530299 A5 JP 2009530299A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- patient
- compound
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 10
- 208000007502 anemia Diseases 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 7
- 102000001554 Hemoglobins Human genes 0.000 claims 6
- 108010054147 Hemoglobins Proteins 0.000 claims 6
- 206010018910 Haemolysis Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 206010022822 Intravascular haemolysis Diseases 0.000 claims 3
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 3
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 3
- 230000006870 function Effects 0.000 claims 3
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- XGUFMAUYGBDFJS-UHFFFAOYSA-N 6'-formyl-2,3,4'-trihydroxy-4,4,7,8a-tetramethylspiro[2,3,4a,5,6,7-hexahydro-1h-naphthalene-8,2'-3h-1-benzofuran]-7'-carboxylic acid Chemical compound C1C(C(=CC(C=O)=C2C(O)=O)O)=C2OC21C1(C)CC(O)C(O)C(C)(C)C1CCC2C XGUFMAUYGBDFJS-UHFFFAOYSA-N 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 102100022002 CD59 glycoprotein Human genes 0.000 claims 2
- 101710172562 Cobra venom factor Proteins 0.000 claims 2
- 229940124073 Complement inhibitor Drugs 0.000 claims 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 102000007079 Peptide Fragments Human genes 0.000 claims 2
- 108010033276 Peptide Fragments Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108091008103 RNA aptamers Proteins 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 108091027076 Spiegelmer Proteins 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000004074 complement inhibitor Substances 0.000 claims 2
- 229960002224 eculizumab Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims 2
- 229950009865 nafamostat Drugs 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 150000002894 organic compounds Chemical class 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 102100030386 Granzyme A Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78307006P | 2006-03-15 | 2006-03-15 | |
| PCT/US2007/006606 WO2007106585A1 (en) | 2006-03-15 | 2007-03-15 | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Division JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530299A JP2009530299A (ja) | 2009-08-27 |
| JP2009530299A5 true JP2009530299A5 (cg-RX-API-DMAC7.html) | 2010-04-02 |
Family
ID=38222520
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US20090220508A1 (cg-RX-API-DMAC7.html) |
| EP (5) | EP2359834B1 (cg-RX-API-DMAC7.html) |
| JP (9) | JP2009530299A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20080110800A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007225044C1 (cg-RX-API-DMAC7.html) |
| BR (2) | BRPI0708909B8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3022097C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2359834T5 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2965283T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE066795T2 (cg-RX-API-DMAC7.html) |
| IL (4) | IL302157A (cg-RX-API-DMAC7.html) |
| MX (2) | MX340784B (cg-RX-API-DMAC7.html) |
| PL (2) | PL3167888T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2359834T (cg-RX-API-DMAC7.html) |
| SI (1) | SI2359834T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007106585A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| KR101463631B1 (ko) | 2006-03-31 | 2014-11-19 | 추가이 세이야쿠 가부시키가이샤 | 항체의 혈중 동태를 제어하는 방법 |
| RU2510400C9 (ru) | 2007-09-26 | 2014-07-20 | Чугаи Сейяку Кабусики Кайся | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr |
| PL2808343T3 (pl) * | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US20110111406A1 (en) | 2008-04-11 | 2011-05-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| PL2328616T3 (pl) | 2008-08-05 | 2015-10-30 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
| BRPI0921237A2 (pt) * | 2008-11-10 | 2015-09-22 | Alexion Pharma Inc | métodos e composições para o tratamento de distúrbios associados ao complemento |
| WO2011057250A1 (en) * | 2009-11-09 | 2011-05-12 | Alexion Pharmaceuticals, Inc. | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
| ES2715638T3 (es) * | 2012-02-20 | 2019-06-05 | Swedish Orphan Biovitrum Ab Publ | Polipéptidos que se unen al complemento humano C5 |
| CN104205155A (zh) * | 2012-03-16 | 2014-12-10 | 亚力克恩制药公司 | 给接受补体抑制剂的患者分配补体抑制药物的方法 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EA201890895A1 (ru) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | Мультивалентные и моновалентные мультиспецифические комплексы и их применение |
| ES2768648T3 (es) * | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
| SMT202100006T1 (it) | 2013-08-28 | 2021-03-15 | Ipc Research Llc | Polipeptidi stabili che si legano al complemento umano c5 |
| EP3039033B1 (en) | 2013-08-28 | 2019-06-19 | Affibody AB | Binding polypeptides having a mutated scaffold |
| WO2015054569A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2895029T3 (es) | 2014-06-12 | 2022-02-17 | Ra Pharmaceuticals Inc | Modulación de actividad del complemento |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| KR102593431B1 (ko) | 2014-09-29 | 2023-10-23 | 케모센트릭스, 인크. | Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체 |
| US20160108357A1 (en) * | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| WO2016061065A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| ES2719876T3 (es) | 2014-10-15 | 2019-07-16 | Alexion Pharma Inc | Métodos para replicar un cultivo celular de producción de eculizumab a gran escala |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| EP3247723A1 (en) | 2015-01-22 | 2017-11-29 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
| RS62630B9 (sr) | 2015-01-28 | 2022-04-29 | Ra Pharmaceuticals Inc | Modulatori aktivnosti komplementa |
| US20180072769A1 (en) | 2015-03-23 | 2018-03-15 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| WO2016160756A2 (en) * | 2015-03-31 | 2016-10-06 | Alexion Pharmaceuticlas, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
| PH12017501834B1 (en) | 2015-04-06 | 2024-01-17 | Arcellx Inc | De novo binding domain containing polypeptides and uses thereof |
| PT3280441T (pt) | 2015-04-07 | 2021-11-30 | Alector Llc | Anticorpos anti-sortilina e métodos para a sua utilização |
| WO2016200627A1 (en) | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| JP7376977B2 (ja) | 2015-06-12 | 2023-11-09 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JP2018520139A (ja) * | 2015-06-26 | 2018-07-26 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法 |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| CN108137702B (zh) | 2015-08-28 | 2023-01-06 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| EP3328885A1 (en) | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| CN108738323B (zh) | 2015-10-06 | 2023-05-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
| US11203634B2 (en) | 2015-10-07 | 2021-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody |
| CN116003596A (zh) | 2015-10-29 | 2023-04-25 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
| PL3685847T3 (pl) | 2015-12-16 | 2023-05-08 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
| SG11201805828YA (en) * | 2016-01-14 | 2018-08-30 | Chemocentryx Inc | Method of treating c3 glomerulopathy |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| KR102866147B1 (ko) | 2016-03-10 | 2025-09-30 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| KR102405278B1 (ko) | 2016-04-22 | 2022-06-07 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 이들의 용도 |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| KR102667023B1 (ko) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| WO2018075758A1 (en) | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| WO2018109588A2 (en) * | 2016-12-16 | 2018-06-21 | Samsung Bioepis Co., Ltd | Stable aqueous anti-c5 antibody composition |
| TW202412841A (zh) | 2017-01-31 | 2024-04-01 | 日商中外製藥股份有限公司 | 抗c5抗體在製造用於治療或預防c5相關疾病的醫藥組合物之用途 |
| MX2019010381A (es) | 2017-03-01 | 2020-01-21 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos de arilo, heteroarilo y heterociclicos para el tratamiento de trastornos medicos. |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| US11459382B2 (en) | 2017-05-22 | 2022-10-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of protein-losing enteropathy in patients |
| WO2018226750A1 (en) | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Single-chain tnf receptor 2 agonist fusion proteins |
| PT3658184T (pt) | 2017-07-27 | 2023-11-29 | Alexion Pharma Inc | Formulações de anticorpo anti-c5 de elevada concentração |
| WO2019028284A1 (en) * | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA |
| TWI811229B (zh) | 2017-08-03 | 2023-08-11 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
| PE20200486A1 (es) | 2017-08-03 | 2020-03-03 | Alector Llc | Anticuerpos anti-cd33 y metodos para utilizarlos |
| EP3700928A1 (en) | 2017-10-26 | 2020-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| JP7285267B2 (ja) | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Ｄドメイン含有ポリペプチドおよびその使用 |
| EP3717004A4 (en) | 2017-12-01 | 2021-12-01 | Children's Hospital Medical Center | COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE |
| MX2020005547A (es) * | 2017-12-04 | 2020-08-20 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
| EP3724226A1 (en) | 2017-12-13 | 2020-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| AR115418A1 (es) | 2018-05-25 | 2021-01-13 | Alector Llc | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS |
| JP7520725B2 (ja) | 2018-05-31 | 2024-07-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与 |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12227568B2 (en) | 2018-06-08 | 2025-02-18 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
| MA52969A (fr) * | 2018-06-19 | 2021-04-28 | Atarga Llc | Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| CN112384532B (zh) | 2018-06-29 | 2025-01-10 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
| PL3618928T3 (pl) | 2018-07-13 | 2023-05-02 | Alector Llc | Przeciwciała antysortylinowe i sposoby ich stosowania |
| CA3106535A1 (en) | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| SMT202400271T1 (it) | 2018-08-01 | 2024-07-09 | Chugai Pharmaceutical Co Ltd | Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5 |
| JP7605734B2 (ja) | 2018-08-31 | 2024-12-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
| US12247073B2 (en) | 2018-08-31 | 2025-03-11 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| MX2021002640A (es) | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| EP4306128A3 (en) | 2018-10-30 | 2024-03-27 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| AU2020291527A1 (en) | 2019-06-11 | 2022-01-20 | Alector Llc | Anti-Sortilin antibodies for use in therapy |
| WO2021022083A2 (en) | 2019-07-31 | 2021-02-04 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| CA3144921A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| TWI886140B (zh) | 2019-07-31 | 2025-06-11 | 瑞士商赫孚孟拉羅股份公司 | 藉由使用抗c5抗體克羅伐單抗（crovalimab）之治療或預防c5相關疾病之劑量及投藥療程 |
| WO2021026160A1 (en) | 2019-08-05 | 2021-02-11 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| KR20220110537A (ko) | 2019-12-05 | 2022-08-08 | 알렉터 엘엘씨 | 항-trem2 항체 사용 방법 |
| US20230035072A1 (en) | 2019-12-12 | 2023-02-02 | Alector Llc | Methods of use of anti-cd33 antibodies |
| BR112022011570A2 (pt) | 2019-12-13 | 2022-12-13 | Alector Llc | Anticorpos anti-mertk e métodos de uso dos mesmos |
| US20230159637A1 (en) | 2020-02-24 | 2023-05-25 | Alector Llc | Methods of use of anti-trem2 antibodies |
| JP2023519962A (ja) | 2020-03-31 | 2023-05-15 | アレクトル エルエルシー | 抗ｍｅｒｔｋ抗体及びその使用方法 |
| KR20230005848A (ko) | 2020-04-03 | 2023-01-10 | 알렉터 엘엘씨 | 항-trem2 항체의 사용 방법 |
| US20230416344A1 (en) | 2020-04-16 | 2023-12-28 | Alexion Pharmaceuticals, Inc. | Methods for treating a complement mediated disorder caused by viruses |
| US20230172930A1 (en) | 2020-05-12 | 2023-06-08 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| US20240101681A1 (en) | 2020-12-02 | 2024-03-28 | Alector Llc | Methods of use of anti-sortilin antibodies |
| US20240174746A1 (en) | 2021-03-18 | 2024-05-30 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
| WO2022204274A1 (en) | 2021-03-23 | 2022-09-29 | Alector Llc | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
| WO2022251446A1 (en) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| CN117642426A (zh) | 2021-06-16 | 2024-03-01 | 艾莱克特有限责任公司 | 双特异性抗MerTK和抗PDL1抗体及其使用方法 |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| JP2025508757A (ja) | 2022-02-23 | 2025-04-10 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| AR129896A1 (es) | 2022-07-12 | 2024-10-09 | Cytomx Therapeutics Inc | INMUNOCONJUGADOS DE EpCAM Y USOS DE ESTOS |
| WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
| AR133963A1 (es) | 2023-09-29 | 2025-11-19 | Trex Bio Inc | MOLÉCULAS DE FUSIÓN VARIANTE TNF-a |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| WO1992010205A1 (en) | 1990-12-06 | 1992-06-25 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| EP0744958B1 (en) | 1994-01-31 | 2003-06-25 | Trustees Of Boston University | Polyclonal antibody libraries |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| JP3971797B2 (ja) | 1994-09-23 | 2007-09-05 | アレクション・ファーマシューティカルズ・インク | 炎症性関節疾患の治療方法 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2399969A1 (en) | 2000-02-10 | 2001-08-16 | Alexion Pharmaceuticals, Inc. | Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| PT1325033E (pt) | 2000-10-10 | 2010-04-15 | Genentech Inc | Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| ATE414720T1 (de) * | 2000-12-05 | 2008-12-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030049260A1 (en) | 2001-07-26 | 2003-03-13 | Leonard Bell | Method of improving cognitive function |
| ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| AU2003223288A1 (en) * | 2002-03-18 | 2003-10-08 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| CN105884893A (zh) | 2002-07-18 | 2016-08-24 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
| AU2003265361A1 (en) | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CN103709250B (zh) | 2002-10-17 | 2016-08-10 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| US20060078307A1 (en) | 2002-12-16 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Personal video recorder method and user interface |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| HUE051878T2 (hu) | 2003-02-10 | 2021-03-29 | Biogen Ma Inc | Immunglobulin készítmény és annak elõállítási módszere |
| JP4869064B2 (ja) | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| MXPA05011486A (es) * | 2003-04-25 | 2006-04-18 | Immunex Corp | Inductores de expresion de proteina recombinante. |
| US20070041972A1 (en) | 2003-05-30 | 2007-02-22 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| CN1822857A (zh) | 2003-06-02 | 2006-08-23 | 阿莱克申药物公司 | 去免疫原性抗cd3抗体 |
| US20050027166A1 (en) | 2003-06-17 | 2005-02-03 | Shinya Matsumoto | Endoscope system for fluorescent observation |
| AT412877B (de) | 2003-07-01 | 2005-08-25 | Miba Gleitlager Gmbh | Schichtwerkstoff |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| CA2560508A1 (en) | 2004-03-24 | 2005-10-06 | Pdl Biopharma, Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| DK1755674T3 (en) * | 2004-05-14 | 2015-02-09 | Alexion Pharma Inc | PROLONGED SURVIVAL OF A allograft by inhibiting complement activity |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| US7470521B2 (en) | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
| AU2006251647A1 (en) | 2005-05-20 | 2006-11-30 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| WO2007002571A2 (en) | 2005-06-23 | 2007-01-04 | Alexion Pharmaceuticals, Inc. | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
| US8309690B2 (en) | 2005-07-01 | 2012-11-13 | Medimmune, Llc | Integrated approach for generating multidomain protein therapeutics |
| WO2007092772A2 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Inc. | Protein formulations |
| JP5722524B2 (ja) | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を抑制することによる同種移植片の生存の延長 |
| AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| CA2650718A1 (en) | 2006-05-01 | 2007-11-15 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| CA2662480C (en) | 2006-09-05 | 2016-11-08 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| TR201807750T4 (tr) | 2010-06-11 | 2018-06-21 | Kyowa Hakko Kirin Co Ltd | Anti-TIM-3 antikoru. |
-
2007
- 2007-03-15 AU AU2007225044A patent/AU2007225044C1/en active Active
- 2007-03-15 ES ES16195355T patent/ES2965283T3/es active Active
- 2007-03-15 IL IL302157A patent/IL302157A/en unknown
- 2007-03-15 PL PL16195355.9T patent/PL3167888T3/pl unknown
- 2007-03-15 EP EP11001632.6A patent/EP2359834B1/en not_active Revoked
- 2007-03-15 BR BRPI0708909A patent/BRPI0708909B8/pt active IP Right Grant
- 2007-03-15 HU HUE16195355A patent/HUE066795T2/hu unknown
- 2007-03-15 CA CA3022097A patent/CA3022097C/en active Active
- 2007-03-15 MX MX2008011735A patent/MX340784B/es active IP Right Grant
- 2007-03-15 ES ES11001632.6T patent/ES2612118T3/es active Active
- 2007-03-15 EP EP07753249A patent/EP2001490A1/en not_active Ceased
- 2007-03-15 EP EP16172335.8A patent/EP3124029A1/en not_active Ceased
- 2007-03-15 KR KR1020087024657A patent/KR20080110800A/ko not_active Ceased
- 2007-03-15 KR KR1020147008290A patent/KR20140057635A/ko not_active Ceased
- 2007-03-15 US US12/225,040 patent/US20090220508A1/en not_active Abandoned
- 2007-03-15 EP EP23198329.7A patent/EP4316465A3/en active Pending
- 2007-03-15 EP EP16195355.9A patent/EP3167888B1/en active Active
- 2007-03-15 BR BR122017024057A patent/BR122017024057B8/pt active IP Right Grant
- 2007-03-15 HU HUE11001632A patent/HUE030105T2/en unknown
- 2007-03-15 WO PCT/US2007/006606 patent/WO2007106585A1/en not_active Ceased
- 2007-03-15 JP JP2009500498A patent/JP2009530299A/ja not_active Withdrawn
- 2007-03-15 SI SI200731886T patent/SI2359834T1/sl unknown
- 2007-03-15 PT PT110016326T patent/PT2359834T/pt unknown
- 2007-03-15 DK DK11001632.6T patent/DK2359834T5/en active
- 2007-03-15 PL PL11001632T patent/PL2359834T3/pl unknown
- 2007-03-15 CA CA2645810A patent/CA2645810C/en active Active
-
2008
- 2008-09-11 IL IL194041A patent/IL194041A/en active IP Right Grant
- 2008-09-12 MX MX2022002589A patent/MX2022002589A/es unknown
-
2012
- 2012-03-22 US US13/426,973 patent/US20120237515A1/en not_active Abandoned
-
2013
- 2013-10-23 JP JP2013219882A patent/JP2014015484A/ja not_active Withdrawn
-
2015
- 2015-12-03 JP JP2015236260A patent/JP6224059B2/ja active Active
-
2016
- 2016-05-06 US US15/148,839 patent/US9718880B2/en active Active
- 2016-09-09 US US15/260,888 patent/US9725504B2/en active Active
- 2016-10-03 US US15/284,015 patent/US9732149B2/en active Active
-
2017
- 2017-02-20 JP JP2017028811A patent/JP2017082017A/ja not_active Withdrawn
- 2017-05-14 IL IL252260A patent/IL252260B/en active IP Right Grant
- 2017-07-05 US US15/642,096 patent/US10590189B2/en active Active
-
2018
- 2018-04-08 IL IL258548A patent/IL258548A/en unknown
- 2018-07-25 JP JP2018139327A patent/JP2018165277A/ja not_active Withdrawn
-
2019
- 2019-10-08 JP JP2019185225A patent/JP2020002176A/ja not_active Withdrawn
-
2020
- 2020-01-23 US US16/750,978 patent/US20200392216A1/en not_active Abandoned
- 2020-02-28 US US16/804,567 patent/US10703809B1/en active Active
-
2021
- 2021-02-17 JP JP2021023314A patent/JP2021073319A/ja not_active Withdrawn
-
2022
- 2022-12-28 JP JP2022211659A patent/JP2023026536A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025091052A patent/JP2025120217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009530299A5 (cg-RX-API-DMAC7.html) | ||
| JP7257374B2 (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| Sekijima et al. | Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses | |
| JP2022521591A (ja) | 腎障害の治療 | |
| KR101197799B1 (ko) | 용혈성 질환을 치료하는 방법 | |
| US12471579B2 (en) | Mouse model of DITRA disease and uses thereof | |
| CN113677706B (zh) | 肝毒性的治疗 | |
| SI2833907T1 (en) | COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA | |
| TWI834025B (zh) | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 | |
| RU2020119942A (ru) | Лечение гнойного гидраденита с использованием антагонистов il-17 | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| KR20200093533A (ko) | Smc 매개성 질환의 치료 | |
| Luck et al. | Differential regulation of cardiac function and intracardiac cytokines by rapamycin in healthy and diabetic rats | |
| Nie et al. | Endothelial microparticles carrying hedgehog-interacting protein induce continuous endothelial damage in the pathogenesis of acute graft-versus-host disease | |
| Dong et al. | Tetrahydroxystilbene glycoside improves microvascular endothelial dysfunction and ameliorates obesity-associated hypertension in obese ZDF rats via inhibition of endothelial autophagy | |
| Shokoples et al. | Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells | |
| RU2016125513A (ru) | Способ лечения нефропатии | |
| BR112020017253A2 (pt) | Ligantes para gm-csf ou receptor gm-csf para uso no tratamento de uma malignidade hematológica em um paciente submetido a alo-hct | |
| Tsai et al. | Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function | |
| Samy et al. | Regulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma | |
| US20180134782A1 (en) | Use of Macrophage inflammatory protein-1Beta (MIP-1Beta) inhibitor to protect pancreas and prevent blood sugar from rising | |
| CN118019545A (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| JPWO2017043630A1 (ja) | 筋力低下症および代謝性疾患の治療薬 | |
| JP6959913B2 (ja) | 肝分泌型代謝制御因子阻害作用による肥満関連疾患治療剤 | |
| US20250215435A1 (en) | Anti-helicase therapy for treatment of repeat expansion disease |